• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

9.360 -0.330 (-3.41%)
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MapLight Therapeutics, Inc. - Common Stock

News headline image
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
October 06, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conference
September 09, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
July 27, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 08, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 01, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
March 02, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
January 09, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
January 05, 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
December 16, 2025
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
December 04, 2025
From MapLight Therapeutics, Inc.
Via GlobeNewswire
News headline image
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 29, 2025
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap